The Active Pipeline at Berube BioVentures presents select sponsor programs currently underway and engaging qualified CDMO partners to participate in evaluation, competitive bidding, and manufacturing execution.
We publish this to do two things: demonstrate that demand is real and invite capable CDMOs to step forward and participate. Timelines are active, scopes are defined, and execution—not ideas—is the constraint. For confidentiality, sponsors are described by category (e.g., “Top 10 Pharma,” “Phage startup,” “EU medtech”) rather than by name.
Active Partnering Opportunities — CDMO Program Summaries
1. Phage startup (consumer health)
Program: Topical + oral phage products (non-drug)
Scope: Phage propagation and purification from characterized bacterial hosts, followed by formulation into oral and topical delivery formats. Includes development of QC assays for potency, stability, and host specificity. Anticipated transition into regulated manufacturing if early market traction is achieved.
Estimated CDMO Lifecycle Value (2–3 Years): Low ~$3–5M | High ~$6–9M
2. Nutraceutical microbiome company
Program: Multi-strain probiotic fermentation + packaging
Scope: Anaerobic and aerobic fermentation of defined microbial consortia, followed by lyophilization, blending, and encapsulation. Requires tight control of strain ratios, viability, and moisture for commercial shelf life. Includes scale-up into regional manufacturing hubs.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$5–7M
3. Synthetic biology startup
Program: Non-GMP recombinant protein (E. coli)
Scope: E. coli fermentation at pilot scale with downstream clarification, TFF, and drying for research and industrial evaluation. Emphasis on rapid iteration, yield optimization, and cost modeling ahead of formal GMP transition.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.6M | High ~$1–2M
4. Global animal health pharma
Program: mAb drug product fill & finish
Scope: GMP formulation and aseptic fill of monoclonal antibody drug product for veterinary indications. Includes stability programs, container closure qualification, and regulatory-ready batch documentation. Fill-finish expected in North America with repeat annual runs.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$8–12M
5. Biotech purification company
Program: Large protein complex DSP (3.6 MDa)
Scope: Custom downstream purification development for very large multimeric protein assemblies. Requires non-standard chromatography, membrane separations, and analytical characterization to preserve bioactivity. Potential handoff into GMP once process is locked.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
6. Phage R&D startup
Program: Full R&D → cGMP phage manufacturing
Scope: End-to-end phage development including host cultivation, amplification, purification, and analytical characterization. Program is expected to transition from R&D into GMP clinical supply with defined master phage banks.
Estimated CDMO Lifecycle Value: Low ~$5–7M | High ~$10–15M
7. Animal health biotech
Program: Engineered Bacillus enzyme feasibility
Scope: Strain engineering and fermentation development for enzyme expression in Bacillus. Includes feasibility runs, DSP development, and early cost-of-goods modeling prior to regulatory engagement.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
8. Veterinary nutraceutical brand
Program: Finished tapeworm treatment product
Scope: Final formulation, blending, filling, and packaging of a veterinary oral treatment product. Focus on consistency, regulatory compliance, and scalable finished-goods manufacturing for regional markets.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–4M
9. Innovation brokerage (large sponsor)
Program: GMM protein production (US)
Scope: Fermentation and purification of genetically modified microbial proteins at GMP or near-GMP standards. Includes scale-up in the United States with full analytical characterization and tech transfer documentation.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
10. Pharma services company
Program: Veterinary injectable formulation
Scope: Development of injectable veterinary formulations including excipient screening, stability studies, and IV bag or vial filling. Designed to support clinical and early commercial supply.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$5–7M
11. Veterinary vaccine manufacturer (EU)
Program: Recombinant subunit vaccine (BEVS)
Scope: Baculovirus expression system process development and GMP manufacturing of recombinant vaccine antigen. Includes tech transfer into EU manufacturing sites and preparation for regulatory submissions.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$12–18M
12. CNS biotech startup
Program: Protein replacement therapy
Scope: Bacterial expression and purification of therapeutic protein candidates with a path toward GMP scale-up. Requires tight control of impurities, aggregation, and stability for CNS delivery considerations.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
13. Early-stage biosimilar startup
Program: Metreleptin GMP manufacturing
Scope: Process development and GMP drug substance manufacturing for a biosimilar peptide hormone. Includes analytical comparability, stability, and preparation for clinical supply.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$7–10M
14. Protein manufacturing startup
Program: Dual protein GMP development
Scope: Parallel development of two recombinant protein processes, including strain optimization, DSP development, and GMP readiness. Designed to de-risk future scale-up and commercialization.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$8–12M
15. Preclinical biotech (IBD)
Program: Enzyme biologic (E. coli)
Scope: Strain development, research cell bank creation, and scale-up fermentation for enzyme therapeutic candidates. Anticipates progression into GMP manufacturing upon preclinical success.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
16. Yeast expression biotech (EU)
Program: VHH expression (Pichia)
Scope: Pichia pastoris fermentation and purification of VHH antibody fragments. Includes process development, scale-up, and GMP manufacturing within EU facilities.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
17. Animal health EV company
Program: Canine MSC-derived EVs
Scope: Production, isolation, and characterization of extracellular vesicles derived from canine mesenchymal stem cells. Requires controlled cell culture, EV purification, and release analytics under GMP-like conditions.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–8M
18. Academic biopreservative project
Program: Bacteriocin purification
Scope: Small-scale fermentation and purification of bacteriocins for food and biopreservation research. Potential expansion into pilot manufacturing if efficacy data supports commercialization.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.7M | High ~$1–2M
19. Probiotic CDMO client
Program: Pichia-expressed food protein
Scope: Fermentation and downstream processing of food-grade recombinant proteins expressed in yeast. Designed for scale-up into commercial food ingredient manufacturing.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–8M
20. Medical device company (EU)
Program: GMP ε-Polylysine adaptation
Scope: Process adaptation and validation of ε-Polylysine production to meet GMP and medical-device quality standards. Includes documentation, process control upgrades, and EU manufacturing alignment.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$5–7M
21. Academic gene therapy lab
Program: Minicircle DNA (research)
Scope: Production of research-grade minicircle DNA using bacterial systems. Includes purification, QC, and scalability assessment for future translational work.
Estimated CDMO Lifecycle Value: Low ~$0.2–0.5M | High ~$1M
22. Companion animal brand
Program: In-vitro CRO → manufacturing bridge
Scope: Transition from in-vitro CRO work into pilot manufacturing of biologically active compounds. Includes process definition, early scale-up, and manufacturing feasibility.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
23. Oncology EV biotech
Program: GMP exosome manufacturing
Scope: GMP production of therapeutic exosomes including upstream cell culture, EV isolation, and release testing. Designed to support early clinical trials with repeat manufacturing campaigns.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
24. Lyophilization services startup
Program: Small-batch peptide DP
Scope: Development and execution of lyophilization cycles for peptide drug products, including fill-finish and stability studies. Focused on clinical and niche commercial supply.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–4M
25. Phage antimicrobial group
Program: cGMP phage bank
Scope: Creation and qualification of GMP master and working phage banks. Includes genomic characterization, safety screening, and long-term storage under regulatory-compliant conditions.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$8–12M
26. Microbiome startup (UK)
Program: Phage / microbiome manufacturing
Scope: Program is moving through NDA and positioning toward UK/EU execution. Likely requires controlled phage production, purification, and formulation readiness with analytics that can support future regulated pathways. Expect multiple rounds of technical exchange as specs lock.
Estimated CDMO Lifecycle Value (2–3 Years): Low ~$3–5M | High ~$7–10M
27. Academic EV program
Program: Engineered EV workflow
Scope: Request focuses on building a streamlined, cost-efficient TFF-based EV isolation workflow with strong QC and marker characterization. Expect method development, reproducibility studies, and scale-up guardrails so the workflow can later transition toward GMP-aligned production.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–4M
28. Global pharma (animal health)
Program: Confidential GMP program
Scope: NDA-first outreach signals a defined program needing a qualified CDMO path rather than exploration. Likely includes GMP DS/DP execution, timeline sensitivity, and tight quality expectations. These programs often expand once initial scope is disclosed and feasibility is confirmed.
Estimated CDMO Lifecycle Value: Low ~$6–10M | High ~$15–25M
29. Veterinary mAb biotech
Program: Master seed generation
Scope: Transition from transient success into Master Seed/Cell Bank generation under USDA-regulated expectations. Requires cell banking strategy, characterization, documentation, and a pathway to stable manufacturing. Often leads into upstream scale-up and initial GMP campaigns once banking is complete.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$8–12M
30. Drug delivery startup
Program: PLGA microspheres
Scope: Translation from lab formulation into clinical-batch GMP microsphere manufacturing. Includes process development for encapsulation, particle sizing control, release profile tuning, and GMP documentation. North American execution preferred based on typical procurement patterns.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$7–10M
31. Veterinary importer consortium
Program: Poultry pharma manufacturing
Scope: This is a distribution-driven sourcing request seeking manufacturers/suppliers with dossiers, packaging formats, and registration support for Egypt. CDMO value depends on whether they want true contract manufacture versus sourcing existing SKUs. If manufacturing is requested, expect recurring purchase cycles.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
32. Academic protein engineering lab
Program: Integrated strain engineering
Scope: They have shake-flask proof-of-concept and now want chromosomal integration to eliminate plasmid instability during scale-up. Scope includes strain build, expression screening, and early process optimization to prepare for fermentation scale-up. This commonly rolls into pilot fed-batch and DSP once a stable producer is identified.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
33. Dermatology pharma
Program: NDA-stage biologics projects
Scope: NDA in motion implies multiple programs or at least one defined development need with quality expectations. Likely involves DS/DP capability mapping, then RFQ-level technical evaluation once details are shared. These accounts can become repeat-work pipelines if the first program lands well.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$12–20M
34. Plant exosome biotech
Program: Plant-derived EV platform
Scope: Platform build request: extraction from fresh plant biomass, purification workflow development, and deep characterization including proteomics/metabolomics/RNA cargo. Requires stabilization strategy work to support both cosmetic and pharma optionality. Expect iterative method development and eventual scale-up once yield/purity targets are established.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
35. Vaccine institute (Asia)
Program: Yeast recombinant protein GMP
Scope: Request is for yeast strain systems, regulatory history, site details, and scale—classic pre-RFP capability verification. Likely flows into tech transfer, process development, and GMP production in a defined geographic footprint (Asia-facing procurement). If they’re a vaccine institute, expect strong documentation and inspection expectations.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
36. Cosmetic encapsulation startup
Program: Custom encapsulation tech
Scope: Early-stage product launch requiring a differentiated encapsulation system for proprietary peptides. Scope typically includes excipient screening, encapsulation method development, stability, and manufacturability assessment. Often leads into pilot runs once prototype performance is proven.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–4M
37. Yeast fermentation company
Program: Viable yeast bulk powder
Scope: Request targets large-quantity viable freeze-dried yeast with high CFU concentration and domestic US shipping. Includes process development if they lack protocol, plus lyophilization optimization and viability QC. If demand is real, recurring supply is likely once specs are met.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
38. Vet-ATMP medtech consortium
Program: MSC GMP production
Scope: Veterinary MSC production under GMP/GLP expectations for in vivo trials, potentially with trial support coordination. Requires sourcing/qualification of animal-derived starting material, expansion, banking, release testing, and documentation. This can evolve into a long-term commercialization supply path if trials progress.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$12–18M
39. Hematology nanoparticle project
Program: Liposomal chemo delivery
Scope: They want fabrication/loading/characterization plus conjugation of a bispecific targeting protein via maleimide chemistry. Scope includes formulation development, conjugation feasibility, particle characterization, and stability. This usually becomes a multi-step dev program before any GMP run.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
40. Strain engineering inquiry
Program: Microbial strain dev
Scope: Light-detail request but likely includes strain construction and early expression screening. Scope may expand quickly once they provide host, target, and intended scale. Often starts as a small paid feasibility then transitions to development if hits are achieved.
Estimated CDMO Lifecycle Value: Low ~$0.5–1M | High ~$2M
41. VHH development biotech
Program: Canine VHH engineering
Scope: They have a humanized VHH binder and want caninization and possibly new canine VHH discovery. Scope could include sequence engineering, expression production, binding verification, and early developability profiling. If success, it can progress into GMP DS manufacturing for veterinary biologics.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
42. Grant-driven exosome project
Program: Exosome isolation
Scope: Short-fuse request for quotes for 1–2L exosome isolation to support a grant submission. Execution may be small initially, but if grant is won it often expands into larger-scale isolation, analytics, and repeat lots.
Estimated CDMO Lifecycle Value: Low ~$0.5–1M | High ~$2–3M
43. Functional EV drug delivery
Program: Loaded exosomes
Scope: Request is specifically for loading external compounds into exosomes, which pushes beyond basic isolation into functionalization methods (e.g., electroporation/sonication/permeabilization). Scope typically includes loading efficiency analytics, EV integrity testing, and stability. Programs like this often expand into scale-up and SOP standardization.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–9M
44. Consulting-led cosmetic polymer
Program: Bio-based cationic polysaccharides
Scope: Sponsor wants renewable/bio-based feedstocks and a cosmetic-grade pathway that stays outside drug regulation. Scope includes fermentation-derived polysaccharide production, chemical functionalization steps, and scale-up planning. Also expects documentation around “bio-based” provenance and supply chain traceability.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
45. Phage oncology biotech
Program: Injectable phage cancer therapy
Scope: Hybrid biologics program: phage particle production with dual displayed therapeutic proteins, plus cell-based potency assays. Scope includes process development, analytical method development, GMP manufacturing strategy, and eventual injectable DP considerations. Rare capability match = high strategic value and multi-step program depth.
Estimated CDMO Lifecycle Value: Low ~$10–15M | High ~$25–40M
46. Ag-biotech startup
Program: Regulatory + manufacturing support
Scope: Request implies end-to-end help: development work, government approval pathways (CFIA/USDA/others), and eventual manufacturing. Scope may include process dev, QC method setup, and packaging formats aligned to agricultural regs. Often starts messy, then sharpens into a defined R&D + scale plan.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
47. Academic vaccine project (EU)
Program: Live GM poultry vaccine
Scope: Manufacturing of an attenuated avian E. coli vaccine with BSL1/BSL2 implications depending on jurisdiction. Scope includes controlled fermentation, lyophilization, containment considerations, and documentation that can support EU/Swiss regulatory expectations. If it moves beyond academic, production scales can grow fast.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
48. Nanoparticle delivery spin-out
Program: Targeted nanocarriers
Scope: Exploratory mapping of CDMOs for future GMP manufacturing of a mitochondria-targeted nanoparticle platform. Scope includes assessing scale-up routes (R&D → pilot → GMP), technical risks, and rough cost/timeline frameworks. If they’re spinning out, expect follow-up once IP/funding solidifies.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
49. Plant EV inquiry
Program: Plant exosome processing
Scope: Direct question on whether plant EV sources are supported. Scope would include extraction from plant material, purification approach selection, and analytics confirming vesicle identity and integrity. Can evolve into a platform project if they have multiple plant sources/products.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–4M
50. VHH biologics inquiry
Program: Discovery → GMP nanobodies
Scope: Request is framed around integrated discovery/engineering plus GMP manufacturing capability. Scope could cover early binder engineering, assay design, expression production, and eventual GMP DS as a handoff. Usually becomes clearer after an intro call clarifies whether they need “discovery” or already have leads.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
51. Early-stage peptibody program
Program: Peptibody therapeutic (early)
Scope: Early manufacturability assessment for a hybrid peptide/biologic modality, typically requiring expression strategy selection, preliminary DSP feasibility, and early analytics to confirm integrity. If they already have a construct, this can move quickly into small-scale expression runs and developability screening. Often becomes a paid feasibility + PD package over the first 6–12 months.
Estimated CDMO Lifecycle Value (2–3 Years): Low ~$2–3M | High ~$5–8M
52. VLP manufacturer search
Program: VLP production with FDA-standard quality
Scope: Sponsor is seeking a CDMO that can run VLP upstream production plus purification and characterization under FDA-aligned quality expectations. Expect early process fit assessment, then development of a reproducible VLP assembly/purification workflow and release analytics. If clinical intent is real, this typically drives multiple lots plus stability over 2–3 years.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$12–18M
53. Next-gen probiotics strategist
Program: Microbial fermentation partner diligence
Scope: Pre-NDA request for ownership/facility structure suggests they’re assessing long-term strategic fit, not just a one-off batch. Scope likely includes fermentation process development, downstream formulation/lyo, and repeat supply of engineered or next-gen probiotic strains. Often includes geography constraints (US/Canada operations) and compliance posture review.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
54. Cell therapy viral vector lab (academic)
Program: Custom HSV-1 vectors + edits
Scope: Custom viral vector engineering plus manufacturing and QC for gene therapy research, including deletion edits and donor/recombinase constructs. Scope includes vector design confirmation, build, small-batch production, and research-grade release characterization. Can expand if they scale into translational grade or multiple constructs.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
55. Cell-free protein spinout
Program: Scale-up of cell-free platform + GMP
Scope: Sponsor has a cell-free production method and needs scale translation and GMP-compatible manufacturing infrastructure. Scope likely includes process intensification, raw material qualification, QC assay development, and pilot demonstrations before GMP execution. Often tied to a pharma client timeline, so speed and documentation matter.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
56. Phage biotech (Africa focus)
Program: Phage CDMO operations + R&D in Canada
Scope: They’re exploring CDMO support for phage therapeutics with a geographic preference for Canadian R&D execution. Scope may include phage bank creation, amplification/purification, formulation, and analytics that match evolving regulatory pathways. Likely starts as feasibility + early development with expansion once clinical strategy solidifies.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
57. Antibody fragment platform startup
Program: GMP manufacturing of antibody components
Scope: Early platform request that usually involves expressing fragments (e.g., VHH/Fab/scFv) in yeast or microbial systems and building a repeatable DSP/analytics package. Expect an initial “platform feasibility” campaign, then 1–2 lead candidates moving into defined GMP runs if data is promising.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
58. Late-stage liposome clinical program
Program: Small molecule liposome formulation (late stage)
Scope: Late-stage implies process is largely defined and sponsor needs a CDMO with validated equipment, GMP controls, and scale capacity for clinical/commercial supply. Scope includes tech transfer, process validation work, long-term stability, and recurring manufacturing campaigns. This is typically a high-pressure procurement with strict QA expectations.
Estimated CDMO Lifecycle Value: Low ~$10–15M | High ~$25–40M
59. Large-scale fungal expression
Program: Filamentous fungi recombinant protein (kg-scale)
Scope: Industrial-scale recombinant protein production using Aspergillus with sterile filtration, DP fill/finish, and potentially powder formats. Capacity is rare globally, so feasibility depends heavily on equipment scale and contamination controls. Over 2–3 years, this usually includes process transfer + at least one major production campaign.
Estimated CDMO Lifecycle Value: Low ~$8–12M | High ~$20–30M
60. Encapsulation / GI delivery
Program: Encapsulation for yeast EVs
Scope: Sponsor needs an encapsulation system to protect EVs through gastric conditions in mice and release in intestines, with strict particle size constraints for feeding. Scope includes formulation screening, release profiling, stability under GI simulation, and small-batch production for preclinical studies. Could expand into larger in vivo studies if efficacy is shown.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
61. LNP miRNA delivery
Program: miR-126 mimic LNP (muscle targeting)
Scope: Custom LNP formulation with non-standard biodistribution (muscle-preferential, liver-sparing) implies iterative formulation development plus in vitro/in vivo characterization. Scope includes lipid selection, potential ligand conjugation, particle analytics, and pilot batch production sized for animal studies. If they get traction, GMP interest can appear quickly.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
62. Anaerobic encapsulation request
Program: Anaerobic next-gen probiotic encapsulation
Scope: They need encapsulation under low-oxygen conditions to preserve strict anaerobes, which requires controlled atmosphere handling during blending, filling, and packaging. Scope includes process design for oxygen exposure minimization, viability testing, and pilot encapsulation runs. If successful, it usually converts into recurring commercial supply.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$5–7M
63. Veterinary microbiome feasibility
Program: Live bacteria veterinary product (feasibility)
Scope: Early-stage manufacturing-led assessment for live microbial product, considering both oral and local routes. Scope typically includes feasibility manufacturing plan, regulatory/compliance posture (GMP vs food cGMP), and early process concepts for fermentation, stabilization, and QC. Often leads into a paid feasibility protocol and pilot batches once concept is selected.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
64. Veterinary viral vector DP
Program: Lyophilization + drug product for viral vector vaccine
Scope: Sponsor is evaluating lyophilization and DP manufacturing for a veterinary viral vector vaccine. Scope includes formulation feasibility, lyo cycle development, aseptic fill, and stability studies aligned to veterinary regulatory frameworks. Likely includes multiple development lots over 2–3 years.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
65. DP CDMO search consultant
Program: Mammalian recombinant protein DP (US-based)
Scope: Capabilities-fit request for US-located facility covering formulation through aseptic fill, including sterile filtration and lyophilization. This implies a structured CDMO selection process and eventual RFP with defined batch sizes, container closure, and release testing panels. If selected, work is typically repeat-based across campaigns.
Estimated CDMO Lifecycle Value: Low ~$6–10M | High ~$15–25M
66. Phage discovery service request
Program: Phage isolation (Fusobacterium, Salmonella, P. gulae)
Scope: Sponsor prioritizes phage isolation against multiple bacterial targets, implying a screening workflow with sample sourcing, host strain work, and plaque purification cycles. Scope includes characterization (host range, lytic activity), phage banking, and early documentation so hits can progress into manufacturing development later. Korea-based sponsor suggests cross-border shipping and documentation considerations.
Estimated CDMO Lifecycle Value: Low ~$0.8–1.5M | High ~$2–3M
67. Oral solid dispersion pharma (EU)
Program: HME / spray-drying dispersion capability mapping
Scope: Pre-RFP questionnaire to validate equipment (e.g., Leistritz 27), solvent handling, and scale capabilities for HME and/or SDD. Scope often converts into a formal RFP with process development runs and tech transfer once shortlist is formed. EU sponsor means audit readiness and documentation quality will be evaluated early.
Estimated CDMO Lifecycle Value: Low ~$6–10M | High ~$15–25M
68. Kombucha/probiotic beverage brand
Program: Carrier-free high-potency probiotic supply
Scope: They want pure, excipient-free probiotic powders at high CFU/g, GRAS-aligned, for ready-to-drink beverage use. Scope includes strain sourcing/qualification, high-potency fermentation/harvest, drying without added carriers, and tight viability/stability QC. Could become recurring supply if specs are achievable.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–9M
69. Exosome encapsulation vendor
Program: Protein-loaded exosomes (95 kDa)
Scope: Sponsor requests exogenous loading of a large protein into exosomes, implying method screening and analytics to prove loading efficiency and EV integrity. Scope likely includes optimization runs, QC characterization, and small-batch supply for proof-of-concept. If successful, expect scale-up and repeat lots.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–9M
70. Microbiome therapy bank
Program: Lyophilization lab consulting + validation
Scope: Consulting-heavy request for lyophilization parameters, cryoprotectant selection, equipment recommendations, and validation methodology for a microbiota lyophilization lab. If they later outsource manufacturing, it could convert into CDMO services; near-term it’s technical advisory + protocol design.
Estimated CDMO Lifecycle Value: Low ~$0.2–0.5M | High ~$1–2M
71. Probiotics & synbiotics pharma
Program: Lyophilized viable probiotics for supplements
Scope: Capabilities inquiry that typically leads to a defined supplement manufacturing program: strain fermentation, lyophilization, blending, packaging, and QC documentation. Sponsor likely wants MOQs, lead times, and introductory tech pack to move into procurement evaluation.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$5–7M
72. Mammalian CLD + GMP protein
Program: CHO line + banking + API + analytics
Scope: Full CLD request with extensive QC panel and activity assays, plus potential DMF support for INN submission. Scope includes cell line development, MCB/WCB generation, upstream/downstream development, and multi-assay analytical package build-out. Even in 2–3 years, this is heavy development spend and likely at least one GMP campaign.
Estimated CDMO Lifecycle Value: Low ~$10–15M | High ~$25–40M
73. Yeast ingredient manufacturer
Program: Long-term fermentation partnership (Torula yeast cream)
Scope: Ongoing supply partnership request for fermented yeast cream, implying large-scale fermentation capability, predictable schedules, and consistent quality. Scope includes upstream production, harvest handling, and logistics coordination; downstream may remain in-house for the sponsor. These are “sticky” once qualified, often converting into multi-year supply contracts.
Estimated CDMO Lifecycle Value: Low ~$8–12M | High ~$20–30M
74. Nanoplasmid pharma program
Program: Nanoplasmid manufacturing (2026 urgency)
Scope: Sponsor has an existing construct and wants end-to-end nanoplasmid capability and schedule availability in 2026. Scope includes process execution, QC release, documentation, and potentially multiple lots depending on clinical plan. Time sensitivity suggests near-term vendor selection and rapid kickoff.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
75. Postbiotics startup
Program: Microbial/postbiotic manufacturing interest
Scope: Light-detail inquiry but likely tied to postbiotic production (lysates, fractions, or vesicles) requiring fermentation plus downstream processing and stabilization. Scope may expand into defined product formats (powder/capsule) once they share target organism and claim strategy.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
76. Global procurement inquiry (manufacturing locations)
Program: Multi-site manufacturing capabilities review
Scope: Sponsor is requesting confirmation of manufacturing locations and general service coverage before sharing detailed technical requirements. This typically precedes a formal RFI/RFP and implies they are mapping qualified CDMOs for a defined program. Once specs are disclosed, scope often includes capability fit analysis followed by a competitive bid.
Estimated CDMO Lifecycle Value (2–3 Years): Low ~$3–5M | High ~$8–12M
77. VLP production program (FDA quality)
Program: VLP manufacturing and scale-up
Scope: Sponsor is actively seeking a CDMO that can produce virus-like particles under FDA-standard quality, implying defined upstream expression and downstream purification needs. Scope usually includes tech transfer, process optimization, analytics, and at least one clinical-grade lot. Often expands into repeat GMP runs if clinical data progresses.
Estimated CDMO Lifecycle Value: Low ~$6–8M | High ~$15–20M
78. Strategic diligence inquiry (microbial platform)
Program: Next-gen probiotic platform assessment
Scope: Request focuses on company background, ownership, and facility footprint, indicating a strategic diligence phase rather than a one-off batch. Scope likely evolves into fermentation process development, downstream stabilization, and recurring supply once strategic alignment is confirmed.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
79. Pediatric gene therapy vectors (academic → translational)
Program: Custom HSV-1 vector production
Scope: Complex viral vector customization, including gene insertion and deletions, with research-grade production and QC. While academic today, these projects often transition into translational-grade manufacturing if proof-of-concept data is strong. Early scope includes design review, vector build, and small-scale production.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$4–6M
80. Cell-free protein GMP bridge
Program: Cell-free protein production scale-up
Scope: Sponsor has a nontraditional production platform and needs help translating it into GMP-compatible execution. Scope includes process robustness studies, raw material qualification, QC assay definition, and pilot-scale demonstration prior to GMP manufacturing.
Estimated CDMO Lifecycle Value: Low ~$5–7M | High ~$12–18M
81. Phage therapeutics (Canada-based R&D)
Program: Phage development and manufacturing
Scope: Sponsor is exploring phage R&D and manufacturing with a preference for Canadian execution. Scope likely includes phage isolation, amplification, purification, banking, and early regulatory-aligned documentation, with expansion into GMP if clinical path advances.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
82. Antibody fragment discovery platform
Program: Antibody fragment expression and scale-up
Scope: Early platform-level work to establish expression and purification of antibody fragments, typically in yeast or microbial systems. Scope includes feasibility runs, DSP development, analytics, and selection of lead formats before committing to GMP.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
83. Liposomal drug (late-stage clinical)
Program: Liposome formulation and GMP manufacturing
Scope: Late-stage clinical program requiring validated liposome formulation, GMP manufacturing, and long-term stability support. Scope usually includes tech transfer, process validation, multiple GMP lots, and QA support aligned with regulatory filings.
Estimated CDMO Lifecycle Value: Low ~$12–18M | High ~$30–45M
84. Industrial fungal expression
Program: Filamentous fungi recombinant protein
Scope: Large-scale expression using Aspergillus with kg-level annual demand, including sterile filtration and DP formats. Scope includes process transfer, scale execution, contamination control, and at least one major production campaign within 2–3 years.
Estimated CDMO Lifecycle Value: Low ~$10–15M | High ~$25–35M
85. Oral delivery encapsulation (preclinical)
Program: GI-protective encapsulation for EVs
Scope: Development of encapsulation systems to protect extracellular vesicles through gastric transit with controlled intestinal release. Scope includes formulation screening, in vitro GI simulation, particle sizing, and pilot batch production for animal studies.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$4–6M
86. Targeted LNP delivery
Program: miRNA LNP formulation
Scope: Sponsor seeks custom lipid nanoparticle formulations with nonstandard biodistribution, requiring iterative formulation development, ligand strategies, and in vitro/in vivo characterization. Early scope is R&D heavy but often transitions quickly to GMP interest if data is positive.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
87. Anaerobic probiotic encapsulation
Program: Oxygen-sensitive probiotic manufacturing
Scope: Manufacturing and encapsulation under anaerobic or low-oxygen conditions, including process design to preserve viability and pilot encapsulation runs. If performance meets specs, this often becomes a recurring commercial supply relationship.
Estimated CDMO Lifecycle Value: Low ~$3–4M | High ~$7–10M
88. Veterinary microbiome feasibility
Program: Live microbial veterinary product
Scope: Manufacturing feasibility assessment covering oral and local delivery routes, with focus on GMP expectations and live microbial handling. Scope usually starts with process concept design and pilot planning, then advances to pilot batches.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$5–7M
89. Veterinary viral vector DP
Program: Lyophilized viral vector vaccine
Scope: Drug product development including formulation, lyophilization cycle development, aseptic fill, and stability studies aligned with veterinary regulations. Multiple development and qualification batches are typical over 2–3 years.
Estimated CDMO Lifecycle Value: Low ~$5–7M | High ~$12–18M
90. Mammalian DP search (US facility)
Program: Recombinant protein DP manufacturing
Scope: Sponsor is screening US-based CDMOs capable of formulation through aseptic fill-finish and lyophilization. Scope often moves quickly into formal RFP and multi-batch manufacturing once a vendor is selected.
Estimated CDMO Lifecycle Value: Low ~$8–12M | High ~$20–30M
91. Phage discovery pipeline
Program: Targeted phage isolation
Scope: Discovery program focused on isolating phages against specific bacterial genera, including screening, purification, host range testing, and early characterization. Successful hits typically roll into phage banking and process development work.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–5M
92. Oral solid dispersion pharma (EU)
Program: HME / SDD capability qualification
Scope: Pre-RFP capability mapping for hot-melt extrusion and spray-drying dispersion, including equipment verification and solvent handling. This often leads to paid process development runs once vendor shortlist is finalized.
Estimated CDMO Lifecycle Value: Low ~$7–10M | High ~$18–25M
93. High-potency probiotic supply
Program: Carrier-free probiotic fermentation
Scope: Supply of excipient-free, high-CFU probiotic powders for beverage use, requiring optimized fermentation, gentle drying, and tight QC. If specs are met, this usually becomes a repeat commercial supply arrangement.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
94. Exosome loading services
Program: Large-protein exosome encapsulation
Scope: Screening and optimization of methods to load high-MW proteins into exosomes while preserving integrity. Scope includes analytics, pilot batches, and proof-of-concept supply, with scale-up potential if efficacy is demonstrated.
Estimated CDMO Lifecycle Value: Low ~$2–3M | High ~$6–9M
95. Microbiome lyophilization consulting
Program: Process design for microbiota banking
Scope: Technical consulting on cryoprotectants, lyophilization parameters, equipment selection, and validation strategy. Near-term scope is advisory, but can convert into CDMO manufacturing later.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.6M | High ~$1–2M
96. Probiotics & synbiotics manufacturing
Program: Supplement-grade probiotic production
Scope: End-to-end supplement manufacturing including fermentation, lyophilization, blending, packaging, and QC documentation. Sponsor is likely evaluating MOQs and timelines before committing to a long-term supply partner.
Estimated CDMO Lifecycle Value: Low ~$3–4M | High ~$7–10M
97. Mammalian CLD + GMP protein
Program: CHO line development and API manufacturing
Scope: Full CLD program with extensive analytics, MCB/WCB generation, upstream/downstream development, and at least one GMP batch. Even within 2–3 years, this represents heavy development and manufacturing spend.
Estimated CDMO Lifecycle Value: Low ~$12–18M | High ~$30–45M
98. Yeast fermentation supply partnership
Program: Long-term Torula yeast supply
Scope: Ongoing upstream fermentation supply relationship requiring consistent large-scale production and logistics coordination. Once qualified, these programs are sticky and often multi-year with predictable volumes.
Estimated CDMO Lifecycle Value: Low ~$10–15M | High ~$25–35M
99. Nanoplasmid manufacturing (time-sensitive)
Program: GMP nanoplasmid production
Scope: Sponsor has an existing construct and needs rapid confirmation of end-to-end nanoplasmid capability and scheduling for 2026. Scope includes execution, QC, documentation, and possibly multiple lots.
Estimated CDMO Lifecycle Value: Low ~$5–7M | High ~$12–18M
100. Postbiotic manufacturing interest
Program: Postbiotic / microbial fraction production
Scope: Early interest in producing postbiotic materials via fermentation and downstream processing, with stabilization into usable formats. Scope likely expands once target organism and claims are finalized.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$4–6M
101. Strategic CDMO capability inquiry
Program: Broad biologics manufacturing fit assessment
Scope: Sponsor is evaluating CDMO technical depth across biologics modalities prior to sharing program specifics. This typically precedes NDA execution and a defined manufacturing request tied to a funded program.
Estimated CDMO Lifecycle Value: Low ~$4–6M | High ~$10–15M
102. Microfluidic Cartridge Lyophilization: 02/11/2026
Program: In-cartridge freeze-dried immunoassay reagents
Scope: London-based startup exploring feasibility and formulation strategies for lyophilizing antibody-based reagents directly within SLA resin microfluidic cartridges (600 µm channels) or as pre-measured freeze-dried beads. Work includes materials compatibility assessment, stabilizer/formulation strategy, cycle development, activity retention, rehydration behavior, pilot runs, and potential ISO 13485 / IVDR documentation support. Program likely begins as technical feasibility / pilot optimization before scaling into regulated manufacturing.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$8–15M
103. saRNA Production Inquiry: 02/11/2026
Program: Self-amplifying RNA (saRNA) research-grade production
Scope: European sponsor (Switzerland / France nexus) evaluating CDMO capability for end-to-end saRNA workflows, spanning gene synthesis of a replicon construct through in vitro transcription (IVT). Inquiry includes access to or use of VEE (Venezuelan Equine Encephalitis) replicon templates, sequence considerations, and replicon-specific capping strategies. Program likely represents early-stage platform or therapeutic research requiring specialized RNA manufacturing, analytical validation, and process expertise.
Estimated CDMO Lifecycle Value: Low ~$6–10M | High ~$25–45M
104. IVD / ELISA Manufacturing Evaluation: 02/11/2026
Program: ELISA-based in vitro diagnostic (IVD) test manufacturing
Scope: Commercial-stage diagnostics company evaluating CDMO partners for ELISA manufacturing, regulatory compliance, and technical fit. The inquiry indicates a defined program requiring ISO-certified IVD manufacturing capabilities, alignment with established quality systems, and the potential for a long-term supply partnership. Sponsor behavior suggests a structured vendor qualification process rather than exploratory research engagement.
Estimated CDMO Lifecycle Value: Low ~$4–7M | High ~$12–22M
105. Engineered Live Biotherapeutic Product (eLBP): 02/17/2026
Program: Process development & cGMP manufacturing of engineered bacterial LBP
Scope: Therapeutic-stage biotechnology company evaluating CDMO partner for process development and cGMP manufacturing of a bacterial engineered Live Biotherapeutic Product (eLBP). Program includes strain engineering & stability, anaerobic fermentation, formulation/lyophilization, regulatory compliance, and GMP capacity assessment. Engagement pattern signals structured vendor qualification aligned with preclinical advancement.
Estimated CDMO Lifecycle Value: Low ~$6–12M | High ~$40–55M
106. Probiotic Downstream Processing & Spray Drying: 02/17/2026
Program: Bacillus coagulans powder finishing / carrier removal
Scope: Commercial-stage food technology company evaluating toll manufacturing support for downstream processing of Bacillus coagulans spore powder containing carbohydrate carriers. Program includes rehydration, diafiltration & centrifugation, spray drying, and final packaging/blending into defined commercial formats. Engagement signals pilot-scale entry with potential transition toward repeat commercial production volumes.
Estimated CDMO Lifecycle Value: Low ~$1.5–3.5M | High ~$6–12M
107. Mammalian Cell Line Drying Feasibility: 02/17/2026
Program: cGMP spray drying / fluidized bed drying of mammalian cell lines
Scope: Advanced R&D-focused organization preparing grant-supported feasibility work involving spray drying or fluidized bed drying of mammalian cell lines with emphasis on preserving physical integrity. Inquiry represents unconventional processing strategy centered on early technical feasibility rather than immediate regulated manufacturing.
Estimated CDMO Lifecycle Value: Low ~$0.5–2M | High ~$4–8M
108. Animal Health Phage Therapy Manufacturing Inquiry: 02/17/2026
Program: Bacteriophage GMP manufacturing capability assessment
Scope: Regulatory / CMC consultant representing multiple clients assessing CDMO GMP manufacturing capabilities for bacteriophage-based animal health drug programs targeting US and EU markets. Engagement signals early-stage vendor landscape mapping with downstream development, scale-up, and regulatory alignment dependency.
Estimated CDMO Lifecycle Value: Low ~$2–5M | High ~$12–25M
109. Bacteriophage Animal Health Drug Development: 02/17/2026
Program: Phage therapy for E. coli infections in swine
Scope: Animal health-focused sponsor actively seeking CDMO support for development and manufacturing of bacteriophage drug candidate targeting E. coli infections in swine. Inquiry behavior suggests a defined therapeutic program progressing toward development-phase execution with eventual GMP and commercial manufacturing requirements.
Estimated CDMO Lifecycle Value: Low ~$5–9M | High ~$20–30M
110. EU Probiotics Manufacturer (Industry R&D): 03/05/2026
Program: Bacteriocin & metabolite characterization
Scope: In-vitro analytical program focused on determining whether defined probiotic strains produce bacteriocins, including compound identification. Additional metabolite analysis for capric acid production in a specified strain. Requires microbiology assays, compound detection, and analytical profiling. Potential expansion into broader strain characterization and formulation studies.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.05–0.15M | High ~$0.3–0.8M
111. Dental University / Clinical Research Program (India): 03/05/2026
Program: Exosome products for human clinical research
Scope: Sourcing of exosome materials for human clinical research evaluating osseointegration around dental implants. Requires defined origin (MSC/plasma/etc.), regulatory positioning (RUO/GMP), concentration metrics, marker characterization, sterility testing, storage/handling data, pricing, and supporting clinical/preclinical data.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.4–0.9M | High ~$3–7M
112. Global Food / Ingredient Conglomerate (Asia, Procurement): 03/05/2026
Program: Finished dose / supplement OEM manufacturing
Scope: OEM production feasibility for multiple dietary supplement ingredients (some GMO-designated): theanine, creatine, melatonin, caffeine, glutamine. Requires GMP-compliant blending, encapsulation/tableting, QC, packaging, FDA registration, and cGMP certification.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$1.5–4M | High ~$8–20M
113. Emerging Biomanufacturing Initiative (Central Asia): 03/05/2026
Program: Specialty biochemical technology transfer + facility build
Scope: Technology transfer and facility build program centered on manufacturing specialty biochemical products derived from animal tissue. Requires end-to-end support including process design, equipment specification, installation, training, and startup.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$2–5M | High ~$10–30M
114. Bio-Agriculture Company (North America): 03/05/2026
Program: Bacillus fermentation capabilities
Scope: Inquiry regarding Bacillus fermentation capabilities and capacity. Likely includes pilot fermentation, scale-up campaigns, downstream processing, and analytical support.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$1–3M | High ~$6–12M
115. Early-Stage Vaccine R&D Group (EU): 03/05/2026
Program: Chimeric HBsAg VLP production
Scope: Non-GMP production of chimeric HBsAg VLPs for antigenicity assays and mouse challenge studies. Defined path toward CMC studies and GMP scale-up within <12 months. Requires yeast expression/VLP assembly competence, purification optimization, and analytical characterization.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$3–6M | High ~$10–18M
116. High-Growth DTC Food / Fermentation Brand (Multi-region): 03/05/2026
Program: Shelf-stable freeze-dried culture development + manufacturing
Scope: R&D and contract manufacturing partner to replicate and optimize a proven baseline culture into a proprietary, shelf-stable freeze-dried format (not ground-up discovery). Pilot run 10k–20k units, Year 1 volume 50k–75k units. Includes fermentation + freeze-drying and stability work; moving away from current supplier(s).
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.5–1.5M | High ~$4–7M
117. Oncology Biotech Startup (UK/EU): 03/05/2026
Program: Engineered oncolytic vaccinia virus CDMO
Scope: Seeking CDMO for process development and GMP manufacturing of an engineered oncolytic vaccinia virus (defined genomic deletions), including virus banking and potential fill-finish.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$3–7M | High ~$15–30M
118. Supplement Scale-Up Consultant / Intermediary (US): 03/05/2026
Program: Nano-liposomal manufacturing partner search
Scope: Request to connect with a nano-liposomal manufacturer; end-client supplement has scaled beyond current capabilities and is seeking a manufacturing services partner with nano-liposomal focus.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.2–0.6M | High ~$2–5M
119. UK-Based Peptide Brand (RUO / Research Market): 03/05/2026
Program: Sterile fill-finish + lyophilisation into vials (RUO peptides)
Scope: Quote request for sterile fill-finish and lyophilization into vials for research-use peptides. Total 2,000 vials: BPC-157 5 mg (1,000) and TB500 5 mg (1,000). Request includes fill/lyo cost, sterility + endotoxin testing, setup fees, and lead time; exploring alternatives to UK manufacturing.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.05–0.15M | High ~$0.3–0.8M
120. Global Health Nonprofit / Vaccine-Adjacency Program: 03/05/2026
Program: Multivalent polysaccharide conjugate GMP drug product (Phase II)
Scope: Capability inquiry for bacterial fermentation of individual polysaccharides, multivalent polysaccharide conjugation, and complete analytics for polysaccharides, targeting GMP drug product suitable for Phase II.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$5–12M | High ~$25–50M
121. Early-Stage Biotech (Microbial Natural Products): 03/05/2026
Program: Bacillus fermentation optimization (secondary metabolite)
Scope: Sponsor has a Bacillus strain and wants fermentation + optimization for secondary metabolite production; asks about fermentation volumes and lyophilization capability; likely starts as optimization/feasibility then expands into pilot supply.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.3–0.8M | High ~$2–4M
122. Consumer Microbiome / Fermented Foods Startup: 03/05/2026
Program: Powdered fermented milk probiotic (kefir/SCOBY process)
Scope: Development of a powdered fermented milk probiotic using a custom process and real kefir grains (SCOBY). Requires controlled fermentation, drying/stabilization, and QC/reproducibility work.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.5–1.5M | High ~$4–8M
123. Early-Stage Biopharma (E. coli Platform, DS+DP): 03/05/2026
Program: End-to-end E. coli process (preclinical → commercial)
Scope: Seeking CDMO support for an E. coli-based process spanning preclinical, clinical, and commercial scale for both drug substance and drug product.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$3–8M | High ~$20–40M
124. EU CDMO Vendor Mapping / Brokered Capability Reference: 03/05/2026
Program: EU microbial fermentation CDMO pointer
Scope: A capability-mapping style entry pointing to an EU-based microbial fermentation CDMO option with European GMP posture; not a defined scope yet (more like supplier identification).
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.0–0.05M | High ~$0.2M
125. Global Ingredients Company (Cosmetic Market, NA Expansion): 03/05/2026
Program: Commercial scale-out of fermentation-derived cosmetic ingredients
Scope: Two fermentation-derived ingredients already commercializing; seeking CDMO partners in the Americas to globalize production. Implies tech transfer, scale-out, and repeat manufacturing once qualified.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$5–10M | High ~$25–50M
126. Ethanol Quantification (US): 03/06/2027
Program: Low-LOQ ethanol measurement (UPLC-RID)
Scope: US-based sponsor running fermentations needs ethanol quantification below current LOQ using UPLC-RID, with expected concentrations < 3 g/L EtOH. Samples are filtered fermentation supernatant. Request is for per-sample pricing (typically also implies confirming LOQ/LLOD feasibility, calibration curve range, turnaround time, and simple reporting).
Estimated CDMO Lifecycle Value: Low ~$0.01–0.03M | High ~$0.05–0.15M
127. Asia-Based Microbial Processing Inquiry (Bacillus Drying): 03/2026
Program: Spray-drying of bacterial suspension (B. subtilis)
Scope: Inquiry into feasibility of spray-drying a live or inactivated B. subtilis suspension, likely requiring process optimization for viability, stability, and downstream formulation.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.2–0.6M | High ~$1–3M
128. US-Based Probiotic / Supplement Startup: 03/2026
Program: End-to-end probiotic manufacturing support
Scope: Early-stage request for full manufacturing support of a probiotic supplement, likely including fermentation, formulation, scale-up, and commercial production.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.5–1.5M | High ~$3–8M
129. US-Based Formulation / Drying Inquiry: 03/2026
Program: Spray-freeze drying (SFD) / cryogenic spray freezing
Scope: Inquiry into advanced drying technologies for liquid formulations, potentially for biologics or sensitive compounds, including feasibility and process capability.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.15–0.4M | High ~$0.8–2M
130. European Animal Health Biotech: 03/2026
Program: Nanobody caninization (protein engineering)
Scope: Request for nanobody engineering to reduce immunogenicity in dogs, including potential downstream expression, characterization, and development support.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.3–0.8M | High ~$2–5M
131. LATAM Industrial Biotech / Enzyme Development: 03/2026
Program: Pichia pastoris expression system (invertase)
Scope: Development of a recombinant enzyme expression system using yeast, including molecular biology, fermentation optimization, and production strategy.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.25–0.7M | High ~$1–3M
132. US-Based Advanced Cell / Exosome Program: 03/2026
Program: Muse cell-derived exosome production
Scope: Development of a process to convert cultured Muse cells into high-yield exosome products, including upstream cell culture, media optimization, and downstream isolation/lyophilization.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$1–3M | High ~$5–12M
133. US Retail / Beverage Intermediary: 03/2026
Program: Functional beverage co-manufacturing (canned format)
Scope: Request to identify a co-manufacturer for a functional beverage at ~10K unit scale, including formulation, canning, and packaging flexibility.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.1–0.4M | High ~$0.8–2M
134. Nordic Academic / Industrial Biotech Inquiry: 03/2026
Program: Filamentous fungi strain engineering (Trichoderma)
Scope: Exploration of capabilities in filamentous fungi strain engineering and co-culture development, likely involving genetic engineering, fermentation, and enzyme production.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.4–1M | High ~$2–6M
135. US-Based Food/Biotech Company: 03/2026
Program: GMP tech transfer for fermentation-derived food additive
Scope: Transfer of an existing microbial fermentation process to a new manufacturing partner, including scale-up, process validation, and GMP production.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$1–3M | High ~$6–15M
136. Global Animal Health Pharma (EU/US): 03/2026
Program: Veterinary monoclonal antibody (mAb) development + manufacturing
Scope: Full CDMO engagement for mAb development, scale-up, GMP DS/DP manufacturing, and commercial supply, including sterile fill-finish and long-term production planning.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$5–15M | High ~$25–60M
137. Middle East Biopharma (UAE): 03/2026
Program: Recombinant human growth hormone (E. coli platform)
Scope: Tech transfer and optimization of an existing rhGH process, including upstream/downstream development, analytics, GMP manufacturing, and regulatory support.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$3–8M | High ~$15–35M
138. European Pet Health / Postbiotic Company: 03/2026
Program: Industrial-scale postbiotic fermentation (pet applications)
Scope: Scale-up and contract manufacturing of proprietary bacterial fermentation processes, including bioreactor production, QC, traceability, and packaging for commercial distribution.
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$1–3M | High ~$6–15M
139. US-Based Nanomedicine Startup: 03/2026
Program: LNP-encapsulated silver nanoparticle (AgNP) therapeutic
Scope: Formulation and characterization of a targeted nanotherapeutic using lipid nanoparticles and aptamer conjugation, including feasibility, purification, and analytical validation (DLS, zeta, ICP-MS).
Estimated CDMO Lifecycle Value (2–3 yrs): Low ~$0.3–0.8M | High ~$2–6M
140. Viral vector tools company: 03/2026
Program: Hollow fiber TFF feasibility (1L scale)
Scope: Single-run hollow fiber TFF evaluation at 1L scale, likely for viral vector or biologic concentration. Limited scope focused on process feasibility and performance data rather than full development. Potential expansion into process optimization if initial results are successful.
Estimated CDMO Lifecycle Value: Low ~$0.05–0.1M | High ~$0.2–0.4M
141. Global pharma (US sourcing): 03/2026
Program: mAb perfusion manufacturing partner
Scope: Supplier identification for monoclonal antibody production using perfusion systems. Likely includes upstream perfusion development, scale-up, and GMP manufacturing once scope is defined. Early sourcing-stage engagement with potential for multi-program expansion if fit is confirmed.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$15–25M
142. Academic oncology microbiome group: 03/2026
Program: LBP (3-strain anaerobic consortium)
Scope: Transition from preclinical microbiome research into GMP development and manufacturing. Includes anaerobic fermentation, multi-strain process development, analytics, and regulatory documentation to support first-in-human trials. Clear path to clinical entry within ~18–24 months.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$10–15M
143. Diagnostics company (IVD): 03/2026
Program: ELISA CDMO partner selection
Scope: Evaluation of CDMOs for ELISA-based IVD manufacturing. Includes assay transfer, validation, ISO-compliant manufacturing, and potential long-term kit supply. Likely to progress into recurring manufacturing contracts if initial program is awarded.
Estimated CDMO Lifecycle Value: Low ~$0.5–1.5M | High ~$3–8M
144. RNA therapeutics startup: 03/2026
Program: saRNA production (research grade)
Scope: Inquiry for self-amplifying RNA production from gene synthesis through IVT, including replicon design and capping strategies. Early-stage research scope with potential progression into process development and GMP manufacturing if program advances.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.8M | High ~$2–5M
145. Academic tech transfer (Japan): 03/2026
Program: Filamentous fungi strain licensing
Scope: Out-licensing of engineered Aspergillus strains designed to reduce aggregation and improve fermentation efficiency. No defined manufacturing program; value tied to potential internal adoption for process improvement.
Estimated CDMO Lifecycle Value: Low ~$0 | High ~$0.2–1M
146. Independent consultant (multi-client): 03/2026
Program: Early-phase cGMP capability inquiry
Scope: General request for CDMO capabilities in early-phase GMP manufacturing. No defined program or modality; may represent multiple downstream opportunities depending on client portfolio and follow-up specificity.
Estimated CDMO Lifecycle Value: Low ~$0–0.5M | High ~$2–5M
147. European pharma services company: 03/2026
Program: Hormone API purification + fill-finish
Scope: Tech transfer-driven program for purification of HCG, HMG, and FSH APIs with client-provided raw materials and process, plus downstream lyophilized vial fill-finish (25k–50k batches). Includes GMP manufacturing and potential ongoing production cycles.
Estimated CDMO Lifecycle Value: Low ~$5–8M | High ~$12–20M
148. Chemical sourcing company: 03/2026
Program: Bulk SLES supply
Scope: Commodity sourcing request for SLES 70 in bulk quantities. Not aligned with CDMO services; purely distribution/procurement-driven with no development component.
Estimated CDMO Lifecycle Value: Low ~$0 | High ~$0.1–0.3M
149. EV analytics startup (Italy): 03/30/2026
Program: EV characterization advisory + potential platform alignment
Scope: Early-stage, non-commercial discussion focused on understanding EV production, characterization, and QC workflows. No immediate manufacturing ask, but strong alignment with analytical method development, standardization frameworks, and EV quality control strategies. If relationship develops, could evolve into co-development of analytics packages or integration of their tools into CDMO workflows (method validation, release assays, comparability). Currently exploratory but strategically relevant to EV platform positioning.
Estimated CDMO Lifecycle Value: Low ~$0.1–0.3M | High ~$1–3M
150. Academic cytokine program (EU): 03/30/2026
Program: GMP recombinant IFN-α API (intranasal clinical)
Scope: Defined small-scale GMP API production (~200 mg) with high potency requirements for early-phase clinical use. Scope includes expression, purification, potency validation, and GMP release. Drug product handled externally, keeping scope DS-focused. Likely expansion into repeat GMP batches if clinical progress continues.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–10M
151. Biotech (urgent inbound): 03/30/2026
Program: Undefined biologics services (rapid engagement)
Scope: High-intent inbound request with urgency but no defined scope yet. Likely near-term conversion into PD, manufacturing, or analytical services depending on pipeline needs. Signal suggests active program with short sales cycle. Value dependent on modality and stage post-qualification.
Estimated CDMO Lifecycle Value: Low ~$2–5M | High ~$8–15M
152. CMC consultant (commercial spray drying): 03/30/2026
Program: GMP spray drying + scale-up to commercial supply
Scope: API spray drying under GMP with clear trajectory toward metric-ton scale. Scope includes process development, GMP execution, and long-term commercial manufacturing. Requires specialized drying capacity and solvent handling. Strong repeat revenue once process is validated.
Estimated CDMO Lifecycle Value: Low ~$8–12M | High ~$20–35M
153. USA Gov-funded biodefense biotech: 03/30/2026
Program: Multispecific VHH CLD + multi-platform expression
Scope: Government-backed program developing multispecific nanobodies across microbial systems (E. coli, yeast, etc.). Scope includes cell line development, small-scale GMP production, and comparative platform evaluation for efficacy and cost. High technical complexity with strong follow-on potential into GMP manufacturing.
Estimated CDMO Lifecycle Value: Low ~$6–10M | High ~$15–25M
154. Student diagnostic concept (EU): 03/30/2026
Program: Multiplex STI home test feasibility
Scope: Concept-stage inquiry حول multi-pathogen detection in a single home-use format. Scope limited to advisory on feasibility, technologies, and constraints. No near-term lab or manufacturing work expected. Dependent on future funding and technical validation.
Estimated CDMO Lifecycle Value: Low ~$0.05–0.2M | High ~$0.5–2M
155. Small biotech (yeast platform + supply): 03/30/2026
Program: S. cerevisiae engineering + spray-dried biomass
Scope: Combined strain engineering and bulk production request. Includes genetic modification, strain validation, fermentation scale-up, and drying. Potential to convert into recurring supply if product is commercialized. Blends R&D and manufacturing, increasing stickiness.
Estimated CDMO Lifecycle Value: Low ~$3–5M | High ~$8–12M
156. Independent diagnostic developer: 03/30/2026
Program: Binder discovery + assay feasibility
Scope: Early-stage diagnostic project requiring antibody/binder strategy, assay format evaluation, and feasibility testing. Likely begins as a small discovery engagement with uncertain downstream expansion. Growth depends on biomarker validation and funding.
Estimated CDMO Lifecycle Value: Low ~$0.5–1.5M | High ~$3–6M
157. EU nutraceutical / probiotic brand: 03/30/2026
Program: Probiotic lozenge (direct compression, GMP supplement)
Scope: Defined RFQ for 100k-unit production including formulation validation, probiotic stabilization, manufacturing, packaging, and QC. Key challenges include CFU retention and moisture control. Likely to convert into repeat manufacturing and product line expansion if successful.
Estimated CDMO Lifecycle Value: Low ~$2–4M | High ~$6–10M
158. US-based synbio company (E. coli fermentation): 04/2026
Program: E. coli inclusion body production
Scope: Contract fermentation of a recombinant protein (~192aa) expressed in E. coli, with delivery of washed inclusion bodies for downstream purification by the client. Two operating models requested: client-supplied strain or in-house strain development. Annual demand ~30–50 kg inclusion bodies at ~30% protein content. Defined, recurring manufacturing program with stable volume expectations.
Estimated CDMO Lifecycle Value: Low ~$0.8–2M | High ~$2–4M
159. US-based beauty biotech startup: 04/2026
Program: Recombinant protein expression + fill/finish
Scope: Expression and purification of a novel protein for cosmetic applications, including QC (CoA, MSDS), stability studies, and potential fill/finish with multi-vendor inputs. Early-stage but requesting near end-to-end CDMO support from development through production.
Estimated CDMO Lifecycle Value: Low ~$0.2–0.4M | High ~$0.8–1.5M
160. US-based research organization (pDNA): 04/2026
Program: Plasmid DNA development + preclinical supply
Scope: Production of research-grade plasmid (~7.5kb) for in vitro and small animal studies, scaling to ~10 mg pre-GMP/GMP-like material for IND-enabling studies. Clear transition from research to preclinical development.
Estimated CDMO Lifecycle Value: Low ~$0.15M | High ~$0.5–0.8M
161. Canada-based biotech (LNP drug): 04/2026
Program: LNP therapeutic development
Scope: Engineering-grade LNP material for GLP tox studies, including formulation development, process optimization, and early scale-up toward clinical readiness.
Estimated CDMO Lifecycle Value: Low ~$0.5M | High ~$1.5–3M
162. EU-based mRNA platform company: 04/2026
Program: Capless mRNA platform
Scope: Introduction of a proprietary mRNA platform with improved expression and reduced cost. Not a direct CDMO manufacturing request; potential licensing or technology partnership opportunity.
Estimated CDMO Lifecycle Value: Low ~$0 | High ~$1M+
163. US-based biotech (mRNA/LNP therapeutic): 04/2026
Program: mRNA/LNP therapeutic development
Scope: Preclinical-stage program progressing toward clinical trials. Includes process development, scale-up, and GMP manufacturing for clinical supply.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–6M
164. US-based biotech (platelet-derived product): 04/2026
Program: Platelet-derived biologic (DSP + fill/finish)
Scope: ISO 7 downstream processing and ISO 5 sterile fill into 10R vials followed by lyophilization. Product derived from infusion-grade platelets with complex biologic handling requirements.
Estimated CDMO Lifecycle Value: Low ~$0.8–1.5M | High ~$2–4M
165. UK-based biotech (RNA nanoparticles): 04/2026
Program: RNA nanoparticle delivery platform
Scope: Process development for a polysaccharide/lipid RNA delivery system, including formulation optimization and early scale-up. Platform-level opportunity with potential expansion.
Estimated CDMO Lifecycle Value: Low ~$0.5M | High ~$1.5M
166. US-based precision fermentation startup: 04/2026
Program: Microalgae protein fermentation (food-grade)
Scope: Industrial-scale fermentation (1,000–5,000L), fed-batch processing under challenging conditions, downstream processing, enzymatic hydrolysis, filtration, and spray drying to final powder. B2B ingredient production.
Estimated CDMO Lifecycle Value: Low ~$1.5–3M | High ~$5–10M+
167. UK-based supplement brand: 04/2026
Program: Multi-strain probiotic capsules
Scope: GMP manufacturing (~25–30K units) using delayed-release capsules, clean-label positioning, and branded strains. Cost-sensitive DTC model with defined COGS targets.
Estimated CDMO Lifecycle Value: Low ~$0.15–0.3M | High ~$0.5–0.8M
168. US-based supplement company (Canada expansion): 04/2026
Program: Multi-category supplement manufacturing
Scope: Broad partner search across probiotics, capsules, tablets, powders, gummies, and liquids. Includes regulatory support, white-label/private label, pilot runs, and long-term production.
Estimated CDMO Lifecycle Value: Low ~$0.5–1.5M | High ~$2–5M
169. US-based regulatory-led supplement program: 04/2026
Program: Akkermansia-based supplement
Scope: Development and manufacturing of microbiome-based supplement including sourcing, formulation, and NDIN regulatory support.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.8M | High ~$1–2M
170. EU-based pharma company: 04/2026
Program: Sterile spray drying + fill-finish
Scope: Aseptic spray drying of pharmaceutical formulations combined with sterile fill into advanced formats (prefilled syringes, gels). Long-term manufacturing partnership potential.
Estimated CDMO Lifecycle Value: Low ~$1–2M | High ~$3–7M
171. EU-based technology company: 04/2026
Program: CO₂ extraction + nanoparticle encapsulation
Scope: Technology collaboration involving supercritical CO₂ extraction and nanoparticle/LNP encapsulation. Not a direct manufacturing request; potential integration into future programs.
Estimated CDMO Lifecycle Value: Low ~$0 | High ~$1–3M
172. EU-based supplement RFQ: 04/2026
Program: Probiotic lozenge (direct compression)
Scope: Development and manufacturing of ~100K lozenges containing S. salivarius K12 with strict CFU stability requirements. Includes formulation, moisture control, sourcing, and GMP documentation.
Estimated CDMO Lifecycle Value: Low ~$0.15–0.3M | High ~$0.5–0.9M
173. EU-based biotech: 04/2026
Program: GMP yeast cell banking
Scope: Production, storage, and transport of master and working cell banks (Yarrowia lipolytica), including QC and GMP documentation.
Estimated CDMO Lifecycle Value: Low ~$0.5–0.8M | High ~$1–1.2M
174. Clinical-stage biotech: 04/2026
Program: GMP bacteriophage manufacturing
Scope: Full GMP DS and DP manufacturing for bacteriophage clinical supply, including fermentation, purification, QC, and regulatory support. Multi-batch expansion likely.
Estimated CDMO Lifecycle Value: Low ~$1–3M | High ~$5–10M+
175. US-based individual (compassionate-use): 04/2026
Program: Phage therapy (single patient)
Scope: Custom phage identification, amplification, and small-scale purification under non-standard conditions. Not scalable CDMO work.
Estimated CDMO Lifecycle Value: Low ~$0.005–0.015M | High ~$0.025–0.075M
176. EU oral care company: 04/2026
Program: Oral microbiome / postbiotic development
Scope: Development and supply of postbiotic ingredients targeting gingivitis and microbiome modulation. Includes screening, formulation, and ongoing supply potential.
Estimated CDMO Lifecycle Value: Low ~$0.3–0.5M | High ~$0.8–1.2M
177. EU biotech: 04/2026
Program: Oncolytic virotherapy (clinical entry)
Scope: GMP manufacturing of oncolytic virus for clinical trials, including upstream production, downstream processing, fill-finish, and regulatory release. High complexity with strong expansion potential.
Estimated CDMO Lifecycle Value: Low ~$4–7M | High ~$10–18M
178. US food company: 04/2026
Program: Bacillus strain engineering + tech transfer
Scope: Strain engineering, process development, scale-up, and technology transfer for Bacillus-based food/ingredient systems. Industrial biotech application.
Estimated CDMO Lifecycle Value: Low ~$0.5–1M | High ~$1.5–3M
179. EU/Asia pharma company: 04/2026
Program: Bacillus subtilis probiotic manufacturing
Scope: End-to-end supplement production including formulation, encapsulation, and powder filling using client-supplied strains. Multi-format (capsule + sachet).
Estimated CDMO Lifecycle Value: Low ~$0.6–1M | High ~$1.5–3M
180. US-based biotech: 04/2026
Program: Live biotherapeutic (DS + DP)
Scope: GMP manufacturing of live bacterial therapeutic including fermentation, downstream processing, and drug product formulation. Clinical-stage trajectory.
Estimated CDMO Lifecycle Value: Low ~$1.5–3M | High ~$4–8M
181. US-based startup: 04/2026
Program: Canine therapeutic antibodies
Scope: Early-stage biologics company developing antibodies for companion animals. Potential progression from discovery through GMP manufacturing.
Estimated CDMO Lifecycle Value: Low ~$0.2–0.5M | High ~$1–2M
